Edwards Lifesciences Corporation

05/08/2024 | Press release | Distributed by Public on 05/08/2024 14:53

Submission of Matters to a Vote of Security Holders - Form 8-K

Item 5.07 Submission of Matters to a Vote of Security Holders
The final results of voting for each matter submitted to a vote of stockholders at the Annual Meeting, which was held on May 7, 2024, are as follows:

Proposal 1: All the nominees for director listed in Proposal 1 were elected to serve until the Company's next annual meeting of stockholders and until their respective successors are duly elected and qualified as set forth below:

Nominee For Against Abstain Broker Non-Votes
Leslie C. Davis 473,738,064.47 345,701.80 1,585,777.67 30,936,513.00
Kieran T. Gallahue 468,309,861.40 5,841,289.80 1,518,392.74 30,936,513.00
Leslie S. Heisz 465,923,804.47 7,991,526.80 1,754,212.67 30,936,513.00
Paul A. LaViolette 447,816,113.40 25,087,719.80 2,765,710.74 30,936,513.00
Steven R. Loranger 468,748,749.40 5,398,101.80 1,522,692.74 30,936,513.00
Ramona Sequeira 468,877,034.47 5,271,179.80 1,521,329.67 30,936,513.00
Nicholas J. Valeriani 465,402,509.40 8,781,079.80 1,485,954.74 30,936,513.00
Bernard Zovighian 472,046,632.40 2,127,076.80 1,495,834.74 30,936,513.00

Proposal 2: The advisory proposal regarding the Company's named executive officer compensation was approved as set forth below:

For Against Abstain Broker Non-Votes
433,346,235.39 42,323,308.55 0 30,936,513.00

Proposal 3: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was approved as set forth below:

For Against Abstain Broker Non-Votes
453,240,922.47 53,365,134.47 0 0

Proposal 4: The approval of the Company's Amended and Restated Long-Term Stock Incentive Compensation Program was approved as set forth below:

For Against Abstain Broker Non-Votes
453,798,884.40 21,870,659.54 0 30,936,513.00

2